ImageneBio, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
IMA$3.81-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(36,417) | $(38,441) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 3,452 | 15,340 |
| Amortization of right-of-use assets | 526 | 466 |
| Accretion of discounts on marketable securities, net | (13) | (33) |
| Non-cash interest expense | — | 489 |
| Depreciation and amortization expense | — | 6 |
| Gain on early extinguishment of lease liability | — | (149) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 939 | (3,574) |
| Deposits and other non-current assets | (1,039) | (1,277) |
| Accounts payable | (654) | (2,179) |
| Accrued expenses and other current liabilities | 1,578 | (9,945) |
| Deferred revenue | — | (650) |
| Other non-current liabilities | (22) | 15 |
| Operating lease liabilities | (1,744) | (694) |
| Net cash used in operating activities | (33,394) | (40,626) |
| Cash flows from investing activities: | ||
| Cash divested in Non-OX40 divestiture | — | (5,215) |
| Purchases of marketable securities | (24,604) | (1,485) |
| Maturities of marketable securities | 23,433 | 2,250 |
| Net cash used in investing activities | (1,171) | (4,450) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 146 | 45 |
| Proceeds from issuance of common stock in connection with employee stock purchase plan | 41 | — |
| Proceeds from issuance of pre-funded warrants to purchase common stock, net of issuance costs | 28,034 | — |
| Proceeds from term loan | — | 15,000 |
| Payment of issuance costs in connection with reverse recapitalization | (3,279) | (5,338) |
| Payment of deferred offering costs | (56) | — |
| Cash acquired in connection with reverse recapitalization | — | 54,631 |
| Proceeds from common stock issued in 2025 PIPE Financing, net of issuance costs | — | 71,130 |
| Net cash provided by financing activities | 24,886 | 135,468 |
| Effect of exchange rate changes on cash and cash equivalents | — | 652 |
| Net change in cash and cash equivalents | (9,679) | 91,044 |
| Cash and cash equivalents at beginning of period | 94,532 | 12,118 |
| Cash and cash equivalents at end of period | $84,853 | $103,162 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Change in right-of-use asset and lease liabilities due to contract modification | $81 | $— |
| Deferred offering costs included in accounts payable | $146 | $— |
| Accretion of redeemable convertible preferred shares | $— | $7,046 |
| Reverse recapitalization issuance costs in accrued expenses | $— | $3,500 |
| Exchange of preferred shares into common stock upon closing of reverse recapitalization | $— | $185,049 |
| Forgiveness of term loan upon closing of reverse recapitalization | $— | $22,989 |
| Issuance of promissory note in connection with divestiture | $— | $6,720 |
| Net assets derecognized in connection with Non-OX40 Divestiture | $— | $5,193 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.